Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 4/20 | 0.60 |
| ▸ | BRAF | P15056 | 3/20 | 0.60 |
| ▸ | KDR | P35968 | 4/20 | 0.53 |
| ▸ | TEK | Q02763 | 4/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | CBFB | Q13951 | 2/20 | 0.46 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | IDH2 | P48735 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30822888 | 0.89 | TRPV1 (0.49) | RAF1BRAFKDRTEKDYRK1A | |
| SCHEMBL30822932 | 0.86 | DYRK1A (0.67) | RAF1BRAFKDRTEKDYRK1A | |
| SCHEMBL1998475 | 0.81 | AKR1C3 (0.59) | RAF1BRAFDYRK1ADYRK1BHTT | |
| SCHEMBL30822892 | 0.79 | HDAC11 (0.60) | RAF1BRAFDYRK1ADYRK1BHTT | |
| SCHEMBL30822915 | 0.77 | ALDH1A1 (0.52) | RAF1BRAFKDRTEKDYRK1A | |
| SCHEMBL30822904 | 0.76 | CACNA1H (0.45) | HTT | |
| SCHEMBL30822901 | 0.76 | DYRK1A (0.67) | RAF1BRAFKDRTEKDYRK1A | |
| SCHEMBL4376917 | 0.76 | BRAF (0.59) | RAF1BRAFKDRTEKDYRK1A | |
| SCHEMBL20685327 | 0.74 | POLB (0.56) | RAF1BRAFKDRHTTCBFB | |
| SCHEMBL30822918 | 0.74 | DYRK1A (0.68) | RAF1BRAFKDRTEKDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042743-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | COUNCIL SCIENT IND RES (IN) | 2026-02-12 | — | — | US | claimed |
| EP-4565566-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) | 2025-06-11 | — | — | EP | claimed |
| WO-2024028893-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2024-02-08 | — | — | WO | claimed |
| US-20260042743-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | COUNCIL SCIENT IND RES (IN) | 2026-02-12 | — | — | US | disclosed |
| EP-4565566-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024028893-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042743-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | ACE2, SARS1, NR3C2 | RAF1 2027/4885BRAF 3265/4885KDR 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.